The assessment available on the Wellmedr. website does not create a doctor–patient relationship. Clinical services are provided by OpenLoop Health and other networks of U.S.-licensed clinicians who determine eligibility for GLP-1 treatment based on medical history and assessment responses. Providers retain full discretion to prescribe or decline compounded GLP-1 medications. Compounded medications offered through Wellmedr. are produced in FDA-registered facilities but are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. Results may vary and depend on individual adherence, provider guidance, and lifestyle changes. Wellmedr. does not manufacture compounded medications, and product appearance may differ from website images. Wellmedr. partners with certified U.S. pharmacies to ensure high standards of safety and quality. Medication costs are included in the Wellmedr care coaching program . Ozempic® is FDA-approved for type 2 diabetes treatment but may be prescribed off-label for weight management. All trademarks are the property of their respective owners. Unless otherwise noted, results reflect similar telehealth brands and  patient experiences rather than public clinical studies.